Summit Therapeutics (SMMT.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov20

FactSet analysts downgrade Summit Therapeutics 2025 EPS forecast

12:28

Nov18

FactSet: Summit Therapeutics 2025 EPS Forecast Revised Up to -1.42 USD

12:23

Nov10

FactSet Revises Summit Therapeutics Inc's 2025 EPS Forecast to -1.47 USD

16:23

TD Cowen Analyst Maintains Buy Rating on Summit Therapeutics

13:46

Nov7

Clear Street Analyst Maintains Buy Rating on Summit Therapeutics

18:58

Summit Therapeutics Reports Positive Phase III HARMONi-A Trial Results for Ivonescimab Plus Chemotherapy in EGFR-Mutated Non-Small Cell Lung Cancer

14:01

Schedules & Filings

Schedules

Filings

Oct20

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -231.79 M, EPS -0.3117

Aug11

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -565.71 M, EPS -0.7617

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -62.91 M, EPS -0.0899

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change